{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:55:45Z","timestamp":1790146545578,"version":"4.0.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR200929"],"award-info":[{"award-number":["NIHR200929"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005624","name":"PATH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022902","name":"Saw Swee Hock School of Public Health, National University of Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022902","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-008475"],"award-info":[{"award-number":["INV-008475"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jvacx.2024.100486","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T08:54:13Z","timestamp":1713257653000},"page":"100486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of evidence from clinical trials"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2353-2352","authenticated-orcid":false,"given":"Hilary S.","family":"Whitworth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Mounier-Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gladys","family":"Mbwanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aim\u00e9e R","family":"Kreimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partha","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruanne","family":"Barnabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Drolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Brisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6247-1746","authenticated-orcid":false,"given":"Deborah","family":"Watson-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvacx.2024.100486_b0005","unstructured":"WHO. International Agency for Research on Cancer. The Global Cancer Observatory. Cancer today. https:\/\/gco.iarc.fr\/today\/home2020."},{"key":"10.1016\/j.jvacx.2024.100486_b0010","unstructured":"Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"10.1016\/j.jvacx.2024.100486_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2020.106399","article-title":"HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010\u20132019","volume":"144","author":"Bruni","year":"2021","journal-title":"Prev Med"},{"issue":"43","key":"10.1016\/j.jvacx.2024.100486_b0020","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.15585\/mmwr.mm7043a1","article-title":"Routine Vaccination Coverage \u2013 Worldwide, 2020","volume":"70","author":"Muhoza","year":"2021","journal-title":"MMWRMorbidity Mortality Weekly Report"},{"key":"10.1016\/j.jvacx.2024.100486_b0025","unstructured":"PATH. Global HPV Vaccine Introduction Overview: Projected and current national introductions, demonstration\/pilot projects, gender neutral vaccination programs, and global HPV vaccine introduction maps (2006 2023) https:\/\/www.path.org\/resources\/global-hpv-vaccine-introduction-overview\/2022."},{"issue":"6","key":"10.1016\/j.jvacx.2024.100486_b0030","doi-asserted-by":"crossref","first-page":"e0177773","DOI":"10.1371\/journal.pone.0177773","article-title":"Lessons learnt from human papillomavirus (HPV) vaccination in 45 low- and middle-income countries","volume":"12","author":"Gallagher","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jvacx.2024.100486_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.pvr.2020.100195","article-title":"IPVS statement on \u201cTemporary HPV vaccine shortage: Implications globally to achieve equity\u201d","volume":"9","author":"Garland","year":"2020","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.jvacx.2024.100486_b0040","unstructured":"World Health Organization. Epidemiological Record. Human papillomavirus vaccines: WHO position paper (2022 update). https:\/\/www.who.int\/publications\/i\/item\/who-wer9750-645-672."},{"key":"10.1016\/j.jvacx.2024.100486_b0045","unstructured":"Single-Dose HPV Vaccine Evaluation Consortium. Review of the current published evidence on single-dose HPV vaccination. 4th Edition. 30 May 2022. Available at: https:\/\/www.path.org\/programs\/center-for-vaccine-innovation-and-access\/single-dose-hpv-vaccine-evaluation-consortium\/."},{"issue":"37","key":"10.1016\/j.jvacx.2024.100486_b0050","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1016\/j.vaccine.2022.06.065","article-title":"Human papillomavirus vaccine effectiveness by number of doses: Updated systematic review of data from national immunization programs","volume":"40","author":"Markowitz","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2024.100486_b0055","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.vaccine.2019.12.017","article-title":"Efficacy and immunogenicity of a single dose of Human Papillomavirus vaccine compared to no vaccination or standard 3 and 2-dose vaccination regimens: a systematic review of evidence from clinical trials","volume":"38","author":"Whitworth","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2024.100486_b0060","doi-asserted-by":"crossref","unstructured":"Barnabas RV, Brown ER, Onono MA, Bukusi EA, Njoroge B, Winer RL, et al. Efficacy of single-dose HPV vaccination among young African women. NEJM Evid. 2022;1(5):EVIDoa2100056.","DOI":"10.1056\/EVIDoa2100056"},{"issue":"10","key":"10.1016\/j.jvacx.2024.100486_b0065","doi-asserted-by":"crossref","first-page":"e1473","DOI":"10.1016\/S2214-109X(22)00309-6","article-title":"Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial","volume":"10","author":"Watson-Jones","year":"2022","journal-title":"Lancet Glob Health"},{"issue":"19","key":"10.1016\/j.jvacx.2024.100486_b0070","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.jvacx.2024.100486_b0075","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1940-6207.CAPR-13-0203","article-title":"Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial","volume":"6","author":"Safaeian","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100486_b0080","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx158","article-title":"Durability of protection afforded by fewer doses of the HPV16\/18 vaccine: the CVT trial","volume":"110","author":"Safaeian","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100486_b0085","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1470-2045(15)00047-9","article-title":"Efficacy of fewer than three doses of an HPV-16\/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials","volume":"16","author":"Kreimer","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100486_b0090","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(15)00414-3","article-title":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","volume":"17","author":"Sankaranarayanan","year":"2016","journal-title":"Lancet Oncol"},{"issue":"32 Pt A","key":"10.1016\/j.jvacx.2024.100486_b0095","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1016\/j.vaccine.2018.02.087","article-title":"Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study","volume":"36","author":"Sankaranarayanan","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2024.100486_b0100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ebiom.2016.06.042","article-title":"A single human papillomavirus vaccine dose improves B cell memory in previously infected subjects","volume":"10","author":"Scherer","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jvacx.2024.100486_b0105","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djaa011","article-title":"Evaluation of durability of a single-dose of the bivalent HPV vaccine: the CVT Trial","author":"Kreimer","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jvacx.2024.100486_b0110","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djaa010","article-title":"Durability of cross-protection by different schedules of the bivalent HPV vaccine: the CVT trial","author":"Tsang","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.jvacx.2024.100486_b0115","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(21)00453-8","article-title":"Vaccine efficacy against persistent human papillomavirus (HPV) 16\/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study","volume":"22","author":"Basu","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100486_b0120","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41541-022-00431-x","article-title":"HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial","volume":"7","author":"Tsang","year":"2022","journal-title":"npj Vaccines"},{"issue":"1","key":"10.1016\/j.jvacx.2024.100486_b0125","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.vaccine.2022.11.044","article-title":"Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination","volume":"41","author":"Joshi","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2024.100486_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.106244","article-title":"Impact of HPV vaccination on HPV-related oral infections","volume":"136","author":"Gheit","year":"2023","journal-title":"Oral Oncol"},{"key":"10.1016\/j.jvacx.2024.100486_b0135","unstructured":"Onono MA, Mugo N, Brown E, Bukusi E, Njoroge B, Winer R, et al. A randomized trial of single-dose HPV vaccination efficacy among young women: final efficacy results. International Papillovirus Conference Washington, USA Abstract #1879. 2023."},{"key":"10.1016\/j.jvacx.2024.100486_b0140","unstructured":"Watson-Jones D, Maxwell C, Kemp T, Mutani P, Whitworth H, Lacey C, et al. Immunogenicity of 1, 2 and 3 doses of Gardasil-9\u00ae and Cervarix\u00ae at 36 months in 9-14 year-old Tanzanian girls: the DoRIS randomised trial. . 23rd world congress of the International Union against Sexually Transmitted Infections Abstract #166. 2022."},{"issue":"10","key":"10.1016\/j.jvacx.2024.100486_b0145","doi-asserted-by":"crossref","first-page":"e1485","DOI":"10.1016\/S2214-109X(22)00306-0","article-title":"Comparing one dose of HPV vaccine in girls aged 9\u201314 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial","volume":"10","author":"Baisley","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jvacx.2024.100486_b0150","unstructured":"Baisley K, Kemp TJ, Mugo N, Whitworth H, Onono MA, Njoroge B, et al. Immunobridging single-dose HPV vaccine in Tanzanian girls (DoRIS trial) to Kenyan women in whom single-dose efficacy has been demonstrated (KEN SHE trial). 23rd world congress of the International Union against Sexually Transmitted Infections Abstract #206. 2022."},{"issue":"1","key":"10.1016\/j.jvacx.2024.100486_b0155","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-060301","article-title":"HPV16\/18 antibody responses after a single dose of nonavalent HPV vaccine","volume":"152","author":"Zeng","year":"2023","journal-title":"Pediatrics"},{"key":"10.1016\/j.jvacx.2024.100486_b0160","article-title":"Innovax bivalent HPV vaccine: safety and immunogenicity of one- and two-dose of Cecolin(r) versus Gardasil(r) in girls 9\u201314 years - phase III interim data International Papillovirus Conference Washington","author":"Agbenyega","year":"2023","journal-title":"USA Abstract #1712"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100486_b0165","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jnci\/djz074","article-title":"Efficacy, safety, and immunogenicity of an escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial","volume":"112","author":"Qiao","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jvacx.2024.100486_b0170","unstructured":"Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania (Add-Vacc). Clinicaltrials.gov: NCT04953130 https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT049531302021."},{"key":"10.1016\/j.jvacx.2024.100486_b0175","unstructured":"Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial. ClinicalTrials.gov: NCT03728881 https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT037288812018."},{"key":"10.1016\/j.jvacx.2024.100486_b0180","unstructured":"Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PRISMA) https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT052379472022."},{"issue":"1","key":"10.1016\/j.jvacx.2024.100486_b0185","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.vaccine.2021.11.041","article-title":"Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: the Costa Rica ESCUDDO trial","volume":"40","author":"Porras","year":"2022","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100486_b0190","doi-asserted-by":"crossref","first-page":"e0267294","DOI":"10.1371\/journal.pone.0267294","article-title":"A community intervention effectiveness study of single dose or two doses of bivalent HPV vaccine (CERVARIX\u00ae) in female school students in Thailand","volume":"17","author":"Jiamsiri","year":"2022","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100486_b0195","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-059968","article-title":"Impact of one and two human papillomavirus (HPV) vaccine doses on community-level HPV prevalence in South African adolescent girls: study protocol and rationale for a pragmatic before-after design","volume":"12","author":"Machalek","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jvacx.2024.100486_b0200","unstructured":"HPV Vaccination in Africa - New Delivery Schedules Alias The HANDS HPV Vaccine Trial (HPV). ClinicalTrials.gov: NCT03832049. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT038320492019."},{"key":"10.1016\/j.jvacx.2024.100486_b0205","unstructured":"Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial (OPTIMO). Clinicaltrials.gov: NCT04265950. https:\/\/www.clinicaltrials.gov\/study\/NCT042659502020."},{"key":"10.1016\/j.jvacx.2024.100486_b0210","unstructured":"Government of India, Ministry of Health & Family Welfare, Immunozation Division. Minutes of the meeting of 18th National Technical Advisory Group on Immunization (NTAGI) held on 26th July 2023, under the Chairpersonship of Secretary, Health and Family Welfare (HFW) at Nirman Bhawan, New Delhi. September 2023. Accessed 28 March 2024. https:\/\/main.mohfw.gov.in\/sites\/default\/files\/Minutes%20of%20Meeting-%2018TH%20NTAGI-%20July%20%272023.pdf2023."},{"key":"10.1016\/j.jvacx.2024.100486_b0215","unstructured":"IARC. Protection from a Single Dose of HPV Vaccine: A major public health impact from IARC studies of vaccine efficacy (IARC Evidence Summary Briefs, No. 4). Lyon, France: International Agency for Research on Cancer. https:\/\/www.iarc.who.int\/evidence-summarybriefs-series\/.2023."},{"key":"10.1016\/j.jvacx.2024.100486_b0220","doi-asserted-by":"crossref","unstructured":"Prem K, Choi YH, B\u00e9nard \u00c9, Burger EA, Mmath LH, Laprise J-F, et al. Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis. medRxiv. 2021:2021.02.08.21251186.","DOI":"10.1101\/2021.02.08.21251186"},{"key":"10.1016\/j.jvacx.2024.100486_b0225","unstructured":"Independent report: JCVI statement on a one-dose schedule for the routine HPV immunisation programme https:\/\/www.gov.uk\/government\/publications\/single-dose-of-hpv-vaccine-jcvi-concluding-advice\/jcvi-statement-on-a-one-dose-schedule-for-the-routine-hpv-immunisation-programme2022."},{"issue":"10","key":"10.1016\/j.jvacx.2024.100486_b0230","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/ijc.34054","article-title":"Now or later: Health impacts of delaying single-dose HPV vaccine implementation in a high-burden setting","volume":"151","author":"Burger","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jvacx.2024.100486_b0235","doi-asserted-by":"crossref","unstructured":"Correction: Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial. Cancer prevention research (Philadelphia, Pa). 2016;9(1):116-7.","DOI":"10.1158\/1940-6207.CAPR-15-0373"},{"key":"10.1016\/j.jvacx.2024.100486_b0240","doi-asserted-by":"crossref","unstructured":"Kreimer AR, Herrero R, Sampson JN, Porras C, Lowy DR, Schiller JT, et al. Evidence for single-dose protection by the bivalent HPV vaccine-review of the Costa Rica HPV vaccine trial and future research studies. Vaccine 2018;36(32 Pt A):4774-82.","DOI":"10.1016\/j.vaccine.2017.12.078"},{"issue":"38","key":"10.1016\/j.jvacx.2024.100486_b0245","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1016\/j.vaccine.2020.07.017","article-title":"Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines","volume":"38","author":"Tsang","year":"2020","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jvacx.2024.100486_b0250","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/CEJ.0000000000000753","article-title":"Immunogenicity and safety of a bivalent, adjuvant system 04-adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15\u201325: a randomized, double-blind, phase III, noninferiority clinical trial","volume":"31","author":"Afshani","year":"2022","journal-title":"Eur J Cancer Prev"},{"issue":"7","key":"10.1016\/j.jvacx.2024.100486_b0255","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jamaoto.2022.1190","article-title":"Outcomes after human papillomavirus vaccination in patients with recurrent respiratory papillomatosis: a nonrandomized clinical trial","volume":"148","author":"Smahelova","year":"2022","journal-title":"JAMA Otolaryngol Head Neck Surg"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224000597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224000597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T03:42:38Z","timestamp":1723520558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136224000597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":51,"alternative-id":["S2590136224000597"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100486","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of evidence from clinical trials","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100486","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100486"}}